AG真人官方

Deutsche Bank AG is offering $3.0 million of 5.00% Fixed-Rate Callable Senior Debt Funding Notes maturing on 29 June 2029. The notes are issued at 100% of principal (minimum 99.65% for certain institutional or fee-based accounts) in minimum denominations of $1,000. Interest is paid annually in arrears each 30 June, calculated on a 30/360 basis. The bank may, at its sole discretion and subject to regulatory approval, redeem the notes at par in whole (not in part) on any semi-annual Optional Redemption Date beginning 30 June 2026 and ending 30 December 2028.

The securities are unsecured, unsubordinated senior preferred obligations intended to qualify as eligible liabilities for the EU Minimum Requirement for Own Funds and Eligible Liabilities (MREL). They are not FDIC-insured and carry typical Deutsche Bank credit risk. As bail-in eligible instruments, holders explicitly consent to possible Resolution Measures under EU/ German banking law, including write-down to zero or conversion into equity should the Single Resolution Board deem the bank non-viable.

Key economics

• Issue/Settlement dates: 26 June 2025 / 30 June 2025
• Principal amount: $3,000,000
• Gross proceeds to issuer: $2,994,000 after 0.35% maximum selling concession ($3.50 per note)
• CUSIP/ISIN: 25161FJF6 / US25161FJF62
• No stock-exchange listing; book-entry only via DTC

Primary risks include issuer credit risk, discretionary early redemption, interest-rate reinvestment risk if called, and potential bail-in loss under EU resolution rules. The small size and standard terms make the issuance largely immaterial to Deutsche Bank鈥檚 capital structure, but investors should assess whether the 5% fixed coupon adequately compensates for the credit and structural risks.

Deutsche Bank AG is offering $3.0 million of 5.00% Fixed-Rate Callable Senior Debt Funding Notes maturing on 29 June 2029. The notes are issued at 100% of principal (minimum 99.65% for certain institutional or fee-based accounts) in minimum denominations of $1,000. Interest is paid annually in arrears each 30 June, calculated on a 30/360 basis. The bank may, at its sole discretion and subject to regulatory approval, redeem the notes at par in whole (not in part) on any semi-annual Optional Redemption Date beginning 30 June 2026 and ending 30 December 2028.

The securities are unsecured, unsubordinated senior preferred obligations intended to qualify as eligible liabilities for the EU Minimum Requirement for Own Funds and Eligible Liabilities (MREL). They are not FDIC-insured and carry typical Deutsche Bank credit risk. As bail-in eligible instruments, holders explicitly consent to possible Resolution Measures under EU/ German banking law, including write-down to zero or conversion into equity should the Single Resolution Board deem the bank non-viable.

Key economics

• Issue/Settlement dates: 26 June 2025 / 30 June 2025
• Principal amount: $3,000,000
• Gross proceeds to issuer: $2,994,000 after 0.35% maximum selling concession ($3.50 per note)
• CUSIP/ISIN: 25161FJF6 / US25161FJF62
• No stock-exchange listing; book-entry only via DTC

Primary risks include issuer credit risk, discretionary early redemption, interest-rate reinvestment risk if called, and potential bail-in loss under EU resolution rules. The small size and standard terms make the issuance largely immaterial to Deutsche Bank鈥檚 capital structure, but investors should assess whether the 5% fixed coupon adequately compensates for the credit and structural risks.

SenesTech has announced an At The Market (ATM) offering of up to $843,069 of common stock through H.C. Wainwright & Co. The offering will be conducted on the Nasdaq Capital Market (SNES) at prevailing market prices, with Wainwright receiving a 3.0% commission on gross sales.

Key details of the offering:

• Last reported stock price: $3.96 per share (June 20, 2025)
• Current market cap (non-affiliate): $8.56 million based on 2,015,291 shares
• Previous sales under Form S-3: $2,011,926.24 in past 12 months

The company specializes in fertility control products for pest management, with two main product lines: ContraPest and Evolve. Recent developments include the January 2024 launch of Evolve Rat and May 2024 launch of Evolve Mouse, both classified as minimum risk pesticides. ContraPest is registered in all 50 states, while Evolve Rat is authorized in 48 states and Evolve Mouse in 36 states.

SenesTech has filed a prospectus for the resale of up to 1,517,608 shares of common stock, comprising 1,498,872 Inducement Shares (exercise price $2.90) and 18,736 Placement Agent Shares (exercise price $3.625). The shares are issuable upon exercise of outstanding warrants.

Key highlights:

• Trading on Nasdaq Capital Market under symbol SNES with last reported price of $3.40 (June 13, 2025)
• Company will receive proceeds from cash exercises of warrants but not from cashless exercises
• Selling stockholders bear selling expenses while company covers registration costs

SenesTech's business focuses on rodent population control through fertility management products ContraPest and Evolve. The company expects continued operating losses and faces risks including product commercialization challenges, market acceptance, and maintaining Nasdaq listing compliance. Forward-looking statements indicate plans for international expansion and using warrant proceeds for R&D, working capital, and potential strategic acquisitions.

The SEC has declared SenesTech's Form S-3 registration statement effective as of June 24, 2025, at 4:00 P.M. The registration statement was filed under file number 333-288097.

Form S-3 is a simplified security registration form used by companies that have already met certain reporting requirements. This effectiveness notice indicates that SenesTech can now proceed with their intended securities offering as outlined in the registration statement.

This development is significant for investors as it means:

• SenesTech can now legally begin selling the registered securities to the public
• The company has satisfied SEC review requirements
• The registration statement contains complete and accurate information according to SEC standards

The Securities and Exchange Commission has declared SenesTech's Form S-3 registration statement effective as of June 24, 2025, at 5:00 P.M. The registration statement was filed under file number 333-286955.

Form S-3 is a simplified security registration form used by companies that have already met specific reporting requirements. This effectiveness notice indicates that SenesTech can now proceed with their planned securities offering as outlined in the registration statement.

This is a significant development for SenesTech (SNES) as it:

• Allows the company to access the public markets for capital raising
• Provides flexibility to issue various types of securities
• Enables shelf offerings for up to three years from the effective date

Cardinal Health, Inc. (CAH) filed a Form 4 indicating that Chief Executive Officer Jason M. Hollar had 5,821 common shares automatically withheld on 06/30/2025 to cover tax obligations arising from the deferred settlement of previously awarded performance share units (transaction code 鈥淔鈥�). The price recorded for the withholding was $167.18 per share, representing an aggregate value of roughly $0.97 million. After the transaction, Hollar鈥檚 direct ownership stands at 191,815 shares.

This is an administrative, non-open-market transaction. No shares were purchased or sold for investment purposes, and there is no indication of a change in the CEO鈥檚 long-term stake. The filing therefore carries minimal fundamental or market impact, serving primarily to update compliance records under Section 16(a).